Endometrial cancer after endometrial ablation or resection for menorrhagia

Kalampokas, Emmanouil; McRobbie, Sarah; Payne, Fiona; Parkin, David E.

doi:10.1002/ijgo.12503

Cited by 10 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to mention that all patient management plans were decided through a consistent single multidisciplinary team. Moreover, we have a comprehensive cancer registry with treatment and outcomes recorded in electronic and written medical records (Kalampokas, McRobbie, Payne, & Parkin, ; Kalampokas, Wilson, Gurumurthy, & Cruickshank, ; Kalampokas, Young, et al, ). Thus, we are confident that our cohort is representative of our population.…”

Section: Discussionmentioning

confidence: 99%

Definitive chemoradiotherapy for cervical cancer: A 11‐year population‐based study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Purpose To assess the recurrence pattern and survival in women treated with definitive chemoradiotherapy for cervical cancer. Methods A retrospective cohort study of women FIGO (2012) stage IB2 to IVA from the Grampian region of Scotland between February 2000 and March 2011. These women were followed up until April 2018. Results A total of 121 eligible women allocated with mean age at treatment 50.59 years (SD = 13.98, range 22–82). Tumours staged: IB2: n = 24 (19.8%), II: n = 45 (37.2%), III: n = 43 (35.5%) and IVA: n = 7 (5.8%). Two (1.7%) women had no available data. Fifty‐five (45.5%) women had recurrence after treatment, and 51 (42.15%) women died from the disease. The sites of recurrence were as follows: central pelvic only (n = 4, 7.27%), pelvic and distant (n = 39, 70.91%) and distant only (n = 12, 21.82%) with median time from end of treatment to first recurrence 44 months (range 2–98), 26 months (range 1–146) and 22 months (range 3–66) respectively. 5‐and 8‐year overall survival was 76.0% (95% CI: 68.8%–84.0%) and 64.4% (95% CI: 56.4%–73.5%) respectively. Conclusions Though overall survival is better than with radiotherapy alone, recurrence occurs up to 10 years after treatment. This raises the issues of how to reduce late recurrence and the appropriateness of current follow‐up protocols.

show abstract

Section: Discussionmentioning

confidence: 99%

Definitive chemoradiotherapy for cervical cancer: A 11‐year population‐based study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Residual endometrial tissue after ablation carries the risk of endometrial cancer [13,30]. However, placement of the LNG-IUS device in the uterus results in the continuous release of levonorgestrel, which in turn suppresses the growth of the remaining endometrium and thereby minimizes the probability of endometrial cancer caused by long-term hormonal activity.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Combined Bipolar Radiofrequency Impedance-Controlled Endometrial Ablation with Levonorgestrel Intrauterine System versus Bipolar Radiofrequency Endometrial Ablation Alone in Women with Abnormal Uterine Bleeding

Zhao

Yang

Feng

et al. 2020

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

This study aims to evaluate the efficacy of the combination of bipolar radiofrequency impedance-controlled endometrial ablation (NovaSure; Hologic Inc., Bedford, MA) and levonorgestrel intrauterine system (LNG-IUS; Mirena; Schering AG, Berlin, Germany) placement in comparison with NovaSure endometrial ablation alone in patients with abnormal uterine bleeding (AUB). Design: A propensity score matching study.

show abstract

“…Unopposed estrogen effect on the endometrium results in excess cell proliferation, endometrial tissue hyperplasia, and malignancy. Obesity is one of the main endogenous sources for unopposed estrogen exposure and the single most important risk factor for EC, even when estrogen levels are normal [ 9 , 31 , 32 ].…”

Section: Classification Of Endometrial Cancermentioning

confidence: 99%

Current Approaches to the Management of Patients with Endometrial Cancer

Kalampokas

Giannis

Kalampokas

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

The incidence of endometrial cancer (EC) is rising and healthcare professionals need to be informed about the latest data on the constant developments in the field of its management. With particular interest in the classification and management of EC, we surveyed current literature, national and international data, and guidelines, as well as the latest studies to present the most recent data regarding the management of EC. It became evident that despite the consensus on low-risk EC, there are still controversies surrounding the management of high-risk EC, especially regarding the role of sentinel lymph node biopsy (SLNB). Our aim is to present the old and new perspectives in the management of EC, the different available surgical routes, the possible desire for fertility preservation, the role of adjuvant therapies and the focus on the advantages and the limitations of the implementation of SLNB in therapeutic strategies. It became evident throughout our search and based on literature data that minimally invasive surgery (MIS) leads to satisfying outcomes, thus becoming gradually the preferred route of surgery, while SLNB could provide essential information and guidance about the overall management needed in cases of both low-risk and high-risk EC.

show abstract

Endometrial cancer after endometrial ablation or resection for menorrhagia

Abstract: The findings indicate that the risk of endometrial cancer could be significantly reduced but not eliminated by EA/R.

Cited by 10 publications

References 36 publications

Definitive chemoradiotherapy for cervical cancer: A 11‐year population‐based study

Definitive chemoradiotherapy for cervical cancer: A 11‐year population‐based study

Comparison of Combined Bipolar Radiofrequency Impedance-Controlled Endometrial Ablation with Levonorgestrel Intrauterine System versus Bipolar Radiofrequency Endometrial Ablation Alone in Women with Abnormal Uterine Bleeding

Current Approaches to the Management of Patients with Endometrial Cancer

Contact Info

Product

Resources

About